Core Viewpoint - The supervisory board of Shandong Linuo Pharmaceutical Packaging Co., Ltd. has confirmed the legality and accuracy of the company's 2025 semi-annual report and related financial documents, ensuring compliance with relevant regulations and reflecting the company's actual situation [1][2][3]. Meeting Details - The 11th meeting of the 4th supervisory board was held on August 8, 2025, with all three supervisors present, either in person or via telecommunication, confirming the meeting's legality and effectiveness [1]. Financial Report Review - The supervisory board reviewed the 2025 semi-annual report and found that the procedures for its preparation and review complied with legal and regulatory requirements, with no false records or significant omissions [1][2]. Fund Usage Compliance - The board confirmed that the use of raised funds during the first half of 2025 adhered to the relevant regulations set by the China Securities Regulatory Commission and the Shenzhen Stock Exchange, with no violations noted [2][3]. Change in Fund Usage - The supervisory board approved a change in the use of part of the raised funds, stating that the decision aligns with the company's current needs and will enhance the efficiency of fund utilization, benefiting the company and its shareholders [3][4]. Acquisition and Investment - The board agreed on a transaction based on the company's business development needs, which aims to integrate resources with Suzhou Chuangyang New Materials Technology Co., Ltd., ensuring reasonable pricing and no significant impact on daily operations [3][4]. Risk Management Enhancement - The board supported the purchase of directors and officers liability insurance, which is expected to optimize the company's risk management system and promote responsible conduct among senior management [4][5].